Phase II trial of irinotecan in patients with metastatic colorectal carcinoma

Journal of Clinical Oncology

Volumn 15, Issue 8, 1997, Pages 2910-2919

  Pitot, Henry C ^a   Wender, Donald B ^a   O'Connell, Michael J ^a   Schroeder, Georgene ^a   Goldberg, Richard M ^a   Rubin, Joseph ^a   Mailliard, James A ^a   Knost, James A ^a   Ghosh, Chirantan ^a   Kirschling, Ron J ^a   Levitt, Ralph ^a   Windschitl, Harold E ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; IRINOTECAN; LOPERAMIDE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER INCIDENCE; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CARCINOMA; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0030818926     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.8.2910     Document Type: Article

References (35)

1. Parker SL, Tong T, Bolden S, et al: Cancer statistics, 1996. CA Cancer J Clin 46:5-27, 1996
2. Moertel CG, Fleming TR, MacDonald JS, et al: Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report. Ann Intern Med 122:321-326, 1995
3. O'Connell MJ, Martenson JA, Wieand HS, et al: Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 331:502-507, 1994
4. Ballantyne GH, Quin J: Surgical treatment of liver metastases in patients with colorectal cancer. Cancer 71:4252-4266, 1993
5. Moertel CG: Chemotherapy for colorectal cancer. N Engl J Med 330:1136-1142, 1994
6. Curreri AR, Ansfield FJ, McIver FA, et al: Clinical studies with 5-fluorouracil. Cancer Res 18:478-484, 1958
7. Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 10:896-903, 1992
8. Poon MA, O'Connell MJ, Wieand HS, et al: Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 9:1967-1972, 1991
9. Erlichman C, Fine S, Wong A, et al: A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 6:469-475, 1988
10. Gottlieb JA, Guarino AM, Call JB, et al: Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Rep 54:461-470, 1970
11. Gottlieb J, Luce JK: Treatment of malignant melanoma with camptothecin (NSC-100880). Cancer Chemother Rep 56:103-105, 1972
12. Moertel CG, Schutt AJ, Reitemeier RJ, et al: Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 56:95-101, 1972
13. Kunimoto T, Nitta K, Tanaka T, et al: Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 47:5944-5947, 1987
14. Hsiang YH, Liu LF: Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48:1722-1726, 1988
15. Kawato Y, Aonuma M, Hirota Y, et al: Intracellular roles of SN-38, a metabolite of camptothecin derivative CFT-11, in the antitumor effect of CPT-11. Cancer Res 51:4187-4191, 1991
16. Taguchi T, Wakui A, Hasegawa K: Phase I clinical study of CPT-11. Research group of CPT-11. Jpn J Cancer Chemother 7:115-120, 1990
17. Rowinsky EK, Grochow LB, Ettinger DS, et al: Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every three weeks. Cancer Res 54:427-436, 1994
18. Abigerges D, Chabot GG, Armand JP, et al: Phase I and pharmacologic studies of the camptothecin analog Irinotecan administered every three weeks in cancer patients. J Clin Oncol 13:210-221, 1995
19. Negoro S, Fukuoka M, Masuda N, et al: Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst 83:1164-1168, 1991
20. Culine S, deForni M, Extra JM, et al: Phase I study of the camptothecin analog CPT-11 using a weekly schedule. Proc Am Soc Clin Oncol 11:110, 1992 (abstr)
21. Rothenberg ML, Kuhn JG, Burris HA III, et al: Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 11:2194-2204, 1993
22. Shimada Y, Yoshino M, Wakui A, et al: Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 11:909-913, 1993
23. Duffy DE, Santner TJ: Confidence intervals for a binomial parameter based on multistage tests. Biometrics 43:81-93, 1987
24. Diem K, Lentner C (eds): Scientific Tables. Basel, Switzerland, Ciba-Geigy, 1970
25. Kaplan E, Meier P: Nonparametric estimation from incomplete observation. J Am Stat Assoc 53:457-481, 1958
26. Abigerges D, Armand JP, Chabot GG, et al: Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 86:446-449, 1994
27. Rothenberg ML, Eckardt JR, Kuhn JG, et al: Phase II trial of irinotecan in patients with progressive of rapidly recurrent colorectal cancer. J Clin Oncol 14:1128-1135, 1996
28. Masuda N, Fukuoka M, Kusunoki Y, et al: CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10:1225-1229, 1992
29. Marsoni S, Hoth D, Simon R, et al: Clinical drug development: An analysis of phase II trials, 1970-1985. Cancer Treat Rep 71:71-80, 1987
30. Conti JA, Kemeny NE, Saltz LB, et al: Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 14:709-715, 1996
31. Rougier P, Bugat R, Douillard JY, et al: Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 15:251-260, 1997
32. Gandia D, Abigerges D, Armand JP, et al: CPT-11-induced cholinergic effects in cancer patients. J Clin Oncol 11:196-197, 1993
33. Hagipantelli R, Saliba F, Misset JL et al: Pathophysiology and therapy of Irinotecan (CPT-11) induced delayed onset diarrhea: A prospective assessment. Proc Am Soc Clin Oncol 14:464, 1995 (abstr)
34. Gupta E, Lestingi TM, Mick R, et al: Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea. Cancer Res 54:3723-3725, 1994
35. Sakata Y, Suzuki H, Kamataki T: Preventive effect of TJ-14, a kampo medicine, on diarrhea induced by irinotecan. Proc Am Soc Clin Oncol 13:456, 1994 (abstr)